This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
Glucosamine sulphate added to usual care was compared against usual care alone. Usual care was defined as any care received from health care providers, with or without physical therapies and investigations, and treatment with prescribed medicines. Chondroitin supplements were excluded from the economic analysis as no clinical advantage over usual care was found in the clinical review.
Location/setting
UK/primary and secondary care.
Methods

Analytical approach:
The analysis was based on a probabilistic Markov model with a lifetime horizon. The authors stated that the perspective of the National Health Service (NHS) was adopted.
Effectiveness data:
A systematic review of the literature was undertaken. Several medical and economic electronic databases were searched. Details of search methods and inclusion/exclusion criteria were reported. Only randomised controlled trials (RCTs) with a follow-up longer than 12 months and systematic reviews of RCTs were included in the analysis. The key clinical input was the probability of undergoing total knee replacement, which was considered as a definition of treatment efficacy and was derived from a published pooled analysis of two RCTs with long follow-up periods (three and five years).
Monetary benefit and utility valuations:
Utility values were derived from a published RCT that reported Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index data, which could be converted into a preference-based utility scale, namely the Health Utilities Index (HUI3). This conversion was based on the results of a Canadian study that included 255 patients with symptomatic knee osteoarthritis.
